Latest news
- Business29 June 2020
Adalvo announces positive CHMP opinion for Livogivatm (Teriparatide injection)
New commercialization agreement in Latin America announced with a large, multinational pharmaceutical firm.
- Business11 May 2020
Adalvo announces new strategic partnerships with Alvogen subsidiary
Adalvo, the new B2B company as part of the Alvogen and Alvotech family, have worked with Lotus pharmaceuticals in Asia to announce 10 new strategic partnership agreements in 2020 with...
- Business05 May 2020
Adalvo looking to create a buzz following its launch
Global pharmaceutical companies Alvogen and Alvotech have introduced a new corporate identity for its B2B operations – called Adalvo – following rapid growth in this area of business in the...
- Business26 March 2020
Message regarding Covid-19
We are living through a very challenging time. The Coronavirus spread is causing changes in everyday life and we are constantly monitoring the situation here at Adalvo
- Business24 March 2020
Alvogen submits European application for generic Pazopanib
Alvogen today announced that it has submitted generic dossier applications for Pazopanib tablets.
- Business24 March 2020
Alvotech and DKSH partner to bring key biosimilar to Asia
Alvotech Hf and DKSH, a leading healthcare provider across 36 emerging countries in South-East Asia, today announced that Alvotech Hf and DKSH have entered into an exclusive license partnership for...
- Business22 March 2020
Successful Kick Off meeting in Zurich
This February the Adalvo team got together in Zurich, Switzerland for a Kick Off meeting.
- Business
Adalvo & JSC Olainfarm to launch a new urology product in 17 countries in 2022-2023
Adalvo is delighted to partner with JSC Olainfarm to launch a new product within the urology segment which is targeted to be the 1st to market opportunity in 17 countries....
- Business
Discover Adalvo's Rare Disease Portfolio
Adalvo's rare disease portfolio encompasses a diverse array of treatments designed to target several rare diseases. Each dossier within our portfolio is developed to improve the quality of life and...
- Business
Explore Adalvo's Comprehensive Diabetes Portfolio
Adalvo's Diabetes portfolio dives into an expansive array of treatments, addressing the diverse requirements of patients and healthcare practitioners. From peptide injections to small molecule oral therapies, Adalvo remains committed...
- Business
Discover Adalvo's Urology Dossiers
Adalvo's Urology Dossiers feature a range of essential products designed to address various urological conditions, including urinary incontinence, overactive bladder, and more. With a focus on quality, efficacy, and patient-centric...
- Business
Adalvo's Anti-Infectives Portfolio
At Adalvo, we are committed to advancing healthcare solutions to combat infectious diseases and enhance patient outcomes worldwide. Explore our diverse portfolio of anti-infections dossiers below.
- Business
Adalvo's Women's Health Portfolio: Empowering Women Through Comprehensive Solutions
At Adalvo, we prioritize women's health by offering a comprehensive range of products designed to address various health needs throughout every stage of a woman's life. From reproductive health to...
- Business
Explore Adalvo's Oncology Portfolio
At Adalvo, we understand the critical importance of providing innovative solutions for oncology patients. Our Oncology Portfolio encompasses a comprehensive range of products designed to address various types of cancer,...